Condition: Lung Adenocarcinoma · Stage IA1 Lung Cancer American Joint Committee on Cancer (AJCC) v8 · Stage IA2 Lung Cancer AJCC v8 · Sponsor: Jonsson Comprehensive Cancer Center
This early phase I trial tests the safety and side effects of dapagliflozin given prior to surgery in patients with stage IA lung adenocarcinoma. Dapagliflozin is approved by the Food and Drug Administration (FDA) for the treatment of diabetes and heart failure. It is an SGLT2 inhibitor. Stage I lung adenocarcinomas express significantly higher levels of the SGLT2 protein than other stages, and research suggests that SGLT2 inhibition improves lung cancer outcomes in patients with diabetes. In this study, dapagliflozin is being used off-label, which means it is being used for a condition that it was not originally approved for by the FDA. The investigational study drug is a neoadjuvant treatment, meaning the drug is given before surgery to try and help make the surgery more effective.
This description comes directly from the study's public registry record.
Amanda R. Gonzalez · 310-794-4376 · rngonzalez@mednet.ucla.edu
Tina Tieu · 310-633-8400 · TinaTieu@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07235280